Clinical Trials Directory

Trials / Completed

CompletedNCT03775200

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
233 (actual)
Sponsor
COMPASS Pathways · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression

Detailed description

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study

Conditions

Interventions

TypeNameDescription
DRUGPsilocybinDose-finding

Timeline

Start date
2019-03-01
Primary completion
2021-07-30
Completion
2021-09-27
First posted
2018-12-13
Last updated
2023-04-24
Results posted
2023-04-24

Locations

25 sites across 10 countries: United States, Canada, Czechia, Denmark, Germany, Ireland, Netherlands, Portugal, Spain, United Kingdom

Regulatory

Source: ClinicalTrials.gov record NCT03775200. Inclusion in this directory is not an endorsement.

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (NCT03775200) · Clinical Trials Directory